ZNF304
Basic information
Region (hg38): 19:57351271-57359898
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ZNF304 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 33 | 37 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 34 | 5 | 0 |
Variants in ZNF304
This is a list of pathogenic ClinVar variants found in the ZNF304 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-57353740-G-A | not specified | Uncertain significance (Apr 28, 2022) | ||
19-57353764-C-T | not specified | Uncertain significance (Aug 12, 2021) | ||
19-57353788-G-C | not specified | Uncertain significance (Nov 18, 2022) | ||
19-57353845-A-T | not specified | Likely benign (Sep 14, 2021) | ||
19-57356051-A-G | not specified | Uncertain significance (Jan 26, 2022) | ||
19-57356075-T-C | not specified | Uncertain significance (Sep 22, 2023) | ||
19-57356077-T-G | not specified | Uncertain significance (Jul 20, 2021) | ||
19-57356258-C-T | not specified | Uncertain significance (Sep 17, 2021) | ||
19-57356311-G-A | not specified | Uncertain significance (Jun 29, 2023) | ||
19-57356372-C-A | not specified | Uncertain significance (Dec 19, 2023) | ||
19-57356372-C-T | not specified | Uncertain significance (Oct 11, 2021) | ||
19-57356398-C-A | not specified | Uncertain significance (Dec 21, 2021) | ||
19-57356405-G-T | not specified | Uncertain significance (Oct 10, 2023) | ||
19-57356427-G-C | not specified | Uncertain significance (Oct 25, 2022) | ||
19-57356441-G-A | not specified | Uncertain significance (Dec 28, 2022) | ||
19-57356443-G-A | not specified | Uncertain significance (May 06, 2022) | ||
19-57356462-C-T | not specified | Uncertain significance (Oct 04, 2022) | ||
19-57356519-A-G | not specified | Uncertain significance (Nov 22, 2023) | ||
19-57356541-T-G | not specified | Uncertain significance (May 21, 2024) | ||
19-57356545-G-A | not specified | Likely benign (Jan 18, 2022) | ||
19-57356636-G-T | not specified | Uncertain significance (Apr 26, 2023) | ||
19-57356645-T-C | not specified | Uncertain significance (Dec 21, 2023) | ||
19-57356649-C-A | not specified | Uncertain significance (Nov 10, 2022) | ||
19-57356674-C-T | not specified | Uncertain significance (Jan 23, 2023) | ||
19-57356678-G-A | not specified | Likely benign (Feb 28, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ZNF304 | protein_coding | protein_coding | ENST00000391705 | 3 | 8592 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0329 | 0.965 | 125720 | 0 | 28 | 125748 | 0.000111 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.53 | 278 | 359 | 0.774 | 0.0000178 | 4431 |
Missense in Polyphen | 69 | 124.24 | 0.55536 | 1533 | ||
Synonymous | 0.148 | 123 | 125 | 0.983 | 0.00000625 | 1180 |
Loss of Function | 2.76 | 6 | 19.0 | 0.316 | 7.95e-7 | 279 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000426 | 0.000423 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000792 | 0.0000791 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000164 | 0.000163 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Acts as transcriptional regulator and plays a role in gene silencing (PubMed:24623306, PubMed:26081979). Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of several tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) by inducing trimethylation of 'Lys-27' of histone H3 (H3K27me3) (PubMed:24623306) in a Polycomb group (PcG) complexes-dependent manner. Associates at promoter regions of TSGs and mediates the recruitment of the corepressor complex containing the scaffolding protein TRIM28, methyltransferase DNMT1 and histone methyltransferase SETDB1 and/or the PcG complexes at those sites (PubMed:24623306). Transcription factor involved in the metastatic cascade process by inducing cell migration and proliferation and gain resistance to anoikis of ovarian carcinoma (OC) cells via integrin-mediated signaling pathways (PubMed:26081979). Associates with the ITGB1 promoter and positively regulates beta-1 integrin transcription expression (PubMed:26081979). Promotes angiogenesis (PubMed:26081979). Promotes tumor growth (PubMed:24623306, PubMed:26081979). {ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:26081979}.;
- Pathway
- Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription
(Consensus)
Recessive Scores
- pRec
- 0.0989
Intolerance Scores
- loftool
- 0.472
- rvis_EVS
- 0.91
- rvis_percentile_EVS
- 89.5
Haploinsufficiency Scores
- pHI
- 0.141
- hipred
- N
- hipred_score
- 0.302
- ghis
- 0.447
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0817
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- angiogenesis;chromatin organization;integrin-mediated signaling pathway;Ras protein signal transduction;positive regulation of cell migration;negative regulation of chromatin binding;positive regulation of angiogenesis;positive regulation of transcription by RNA polymerase II;positive regulation of epithelial cell proliferation;positive regulation of methylation-dependent chromatin silencing;positive regulation of histone H3-K9 trimethylation;positive regulation of histone H3-K27 trimethylation;negative regulation of anoikis
- Cellular component
- nucleus
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;protein binding;metal ion binding;promoter-specific chromatin binding